Abstract N 6-methyladenosine (m6A), the most abundant internal modification in eukaryotic
messenger RNAs (mRNAs), has been shown to play critical roles in various normal …

Despite more than three decades of intensive effort, no effective pharmacological inhibitors
of the RAS oncoproteins have reached the clinic, prompting the widely held perception that …

A G-quadruplex (G4) is a well-known nucleic acid secondary structure comprising guanine-
rich sequences, and has profound implications for various pharmacological and biological …

Following the discovery of BRD4 as a non-oncogene addiction target in acute myeloid
leukaemia (AML),, bromodomain and extra terminal protein (BET) inhibitors are being …

Short hairpin RNA (shRNA) technology enables stable and regulated gene repression. For
establishing experimentally versatile RNAi tools and minimizing toxicities, synthetic shRNAs …

MYC contributes to the pathogenesis of a majority of human cancers, yet strategies to
modulate the function of the c-Myc oncoprotein do not exist. Toward this objective, we have …

Epigenetic pathways can regulate gene expression by controlling and interpreting chromatin
modifications. Cancer cells are characterized by altered epigenetic landscapes, and …

Cancer cells frequently depend on chromatin regulatory activities to maintain a malignant
phenotype. Here, we show that leukemia cells require the mammalian SWI/SNF chromatin …

Using a mouse model of human MLL-AF9 leukemia, we identified the lysine-specific
demethylase KDM1A (LSD1 or AOF2) as an essential regulator of leukemia stem cell (LSC) …

The concept of differentiation therapy emerged from the fact that hormones or cytokines may
promote differentiation ex vivo, thereby irreversibly changing the phenotype of cancer cells …